Author

C. Heeschen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. Parejo-Alonso· 3 shared B. Sainz· 3 shared P. Sancho· 3 shared S. Courtois· 3 shared A. Royo-Garcia· 2 shared L. Penin-Peyta· 2 shared P. Espiau-Romera· 2 shared P. Jagust· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. Parejo-Alonso

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ALK signaling drives tumorigenicity and chemoresistance of pancreatic ductal adenocarcinoma cells

B. Parejo-Alonso, A. Royo-Garcia, P. Espiau-Romera, S. Courtois, A. Curiel-Garcia, S. Zagorac, I. Villaoslada, K. P. Olive, C. Heeschen, P. Sancho

This study shows that ALK signaling promotes tumorigenicity and chemoresistance in pancreatic cancer stem cells, and that ALK inhibitors can reduce CSC content and enhance chemotherapy effectiveness.

bioRxiv · Aug 29, 2022 · PreprintCancer Biology

LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer

D. Delle Cave, S. Buonaiuto, M. Mangini, B. Sainz, A. Di Domenico, T. Teresa Iavazzo, G. Andolfi, C. Cortina Duran, M. Sevillano, C. Heeschen, V. Colonna, M. Corona, A. Cucciardi, M. Di Guida, E. Batlle, , E. Lonardo

This study identifies LAMC2-positive cells as tumor-initiating cells in pancreatic cancer with aggressive properties and shows that targeting TGF-β signaling inhibits metastasis.

bioRxiv · Mar 24, 2022Cancer Biology

PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer

B. Parejo-Alonso, D. Barneda, S. M. Trabulo, S. Courtois, S. Compte-Sancerni, L. Ruiz-Canas, Q. Zheng, J. Tang, M. Chen, Z. Guo, U. Schmitz, P. Irun, L. Penin-Peyta, S. M. Crusz, A. Cano-Galiano, , P. Sancho

This study shows PPAR-delta drives metabolic reprogramming in pancreatic cancer, promoting metastasis, and its inhibition reduces invasiveness.

bioRxiv · Nov 15, 2021 · PreprintCancer Biology

Inhibition of mitochondrial dynamics preferentially targets pancreatic cancer cells with enhanced tumorigenic and invasive potential

S. Courtois, B. de Luxan-Delgado, L. Penin-Peyta, A. Royo-Garcia, B. Parejo-Alonso, P. Jagust, S. Alcala, J. A. Rubiolo, L. Sanchez, B. Sainz, C. Heeschen, P. Sancho

This study shows that inhibiting mitochondrial fission with mDivi-1 selectively kills pancreatic cancer stem cells by causing mitochondrial dysfunction and energy crisis.

bioRxiv · Jan 17, 2021Cancer Biology